Biotech stocks up more than 10% in 2024 with 111% YTD and 72% LW for the best stocks

NORDIC | BIOTECH & HEALTHCARE Your insights to listed Danish & Nordic biotech & healthcare stocks.

The Nordic biotech and healthcare stocks continue on the positive upward trend since the bottom in October 2023. The Danish stocks fared better than the Nordic counterparts for yet another week. Year-to-date the Danish biotech stocks have already delivered a double-digit return.

In the past week, Genmab announced sales of Darzalex in 2023, Evaxion expanded its vaccine development, CS Medica expanded in Australia, Curasight received its first milestone from the Curium deal, and shareholders in SynAct Pharma wants a new board of directors. 12 of the 20 companies had a positive share price development the past week and 12 companies have had a positive share price performance year-to-date.

CS Medica is the best-performing Danish stock year-to-date with a 72% return and Oncozenge AB was the best investment last week.

Stay tuned to the developments of impact companies and stocks in the Nordics with the NORDIC | IMPACT newsletter that helps you to invest more sustainably in the businesses of tomorrow.


Ascendis Pharma

No news the past week


No news the past week


Cessatech announces that management and board have exercised all their warrants of series TO2 (Link)

CS Medica

Danske Bank Extends CS MEDICA’s Credit Line (Link)

CS MEDICA Breaks New Ground in Australia with Registration of CANNASEN® Pain Patch and Launch of its Cosmetic Products (Link)


Curasight A/S Achieves First Milestone under collaboration with Curium Inc. (Link)

Evaxion Biotech

Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets (Link)

Evaxion Announces Completion of ADS Ratio Change (Link)


No news the past week


No news the past week


Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen (Link)

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2023 (Link)

Jyske Bank lowered their price target from 3,225 DKK to 2,850 DKK.


Gubra concludes the research agreement with UK Biotech (Link)

Initiator Pharma

No news the past week

IO Biotech

No news the past week

Pila Pharma

No news the past week


No news the past week

Scandion Oncology

No news the past week

SynAct Pharma

The Board of Directors of SynAct Pharma AB has received a request to convene an EGM (Link)


No news the past week

Zealand Pharma

Zealand Pharma major shareholder announcement: Van Herk Investments (Link)

Y-mAbs Therapeutics

No news the past week


No news the past week



On average, the Danish biotech and healthcare stocks delivered a positive share price performance of the past week of 2%. The most notable news were Genmab announcing sales of Darzalex for 2023, Evaxion expanding its vaccine development, CS Medica breaking ground in Australia, Curasight receiving its first milestone from the Curium deal, and major shareholders in SynAct Pharma wanting a new board of directors. The best stocks year-to-date are CS Medica, Y-mAbs Therapeutics, and Expres2ion Biotech Holding with 59-72% increases already after four weeks of trading. Overall the Danish biotech and healthcare stocks are in positive territory this year with a year-to-date return of 10.1%.

Read more about Curasight (in Danish): Positive studiedata mod lungekræft styrker Curasights stærke kursudvikling

Overview of share price developments the past week, year-to-date, and last twelve months


The past week, the all Nordic index Kapital Partner Nordic Healthcare Index (KPHC) rose 0.4% to 65.10 and the index is slowly continuing its recovery from the all-time low in October of 57.12. In the past 12 months, it has significantly underperformed relative to large caps, while the venture/small cap Kapital Partner Nordic Growth Exchanges index (KPNGX) has followed the KPHC-index’s downward trajectory.

The index development for Kapital Partner Healthcare Index the past 12 months

The KPHC index includes all Nordic healthcare stocks. This means both Novo Nordisk and Genmab as well as Curasight.

46-111% in weekly retrun for the three best performing Nordic biotech & healthcare stocks the past week

Oncozenge AB (111%) (Nordnet) is a Swedish pharmaceutical company that develops treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. After completing phase 2 studies, the company’s product candidate is under further development as a basis for applying for regulatory market approvals and commercialization.

Scandinavian ChemoTech AB (102%) (Nordnet) is a research and development company that has developed the technology Tumor-Specific Electroporation – TSE ™ for the treatment of various cancers. The technology means that electronic pulses are sent to the treated area and the membranes of the tumor cells are opened to reach their DNA. 

In the past week, Scandinavian ChemoTech achieved a ground-breaking milestone in head & neck cancer treatment. Read more (Link).

PMD Device Solutions AB (46%) (Nordnet) is a Swedish biopharmaceutical company. Today, the business is focused on developing peptide-based medicines, which includes treatment from wound care. The products can, for example, be used in the treatment of tendon repair, venous leg ulcers, diabetic foot ulcers, and other chronic wounds. The company previously went by the name Promore Pharma.

Sources: Refinitiv & Nordnet


Udvalgte investeringscases

Ønsker du at modtage et af vores nyhedsbreve? Udfyld venligst formularen nedenunder.

  • Investeringscases – Nyhedsbreve med top aktuelle investeringscases fra de nordiske vækstbørser og life science sektoren, og ugentlige markedsopdateringer..
  • Børsnoteringer – Opdateringer på nye og igangværende børsnoteringer i Skandinavien samt resultaterne af dem. (Nyhedsbrev fra   
  • Nyheder – Nyheder fra og om Kapital Partner, herunder indsigt om kapitalmarkederne og børsnoteringer samt invitation til investormøder og- arrangementer.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*Hvis du ønsker information om vores kommende investeringsforening med fokus på de nordiske vækstbørser, herunder mulighed for at investere, så tilmeld dig nyhedsbrevet Nyheder.


Ønsker du at være en del af Kapital Partners investornetværk, hvor du får adgang til investeringer i selskaber og emissioner, samt indbydelse til investorrettede arrangementer
udfyld venligst formularen her.

Udvalgte cases

Del indlægget på sociale media eller på email.